Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €27.69 EUR
Change Today +0.075 / 0.27%
Volume 0.0
As of 3:51 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

formycon ag (FYB) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/10/15 - €35.00
52 Week Low
06/10/14 - €6.23
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for FORMYCON AG (FYB)

Related News

No related news articles were found.

formycon ag (FYB) Related Businessweek News

No Related Businessweek News Found

formycon ag (FYB) Details

Formycon AG, a biopharmaceutical company, develops and markets biosimilar products. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is based in Planegg, Germany.

Founded in 1999

formycon ag (FYB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

formycon ag (FYB) Key Developments

Formycon AG Reports Preliminary Consolidated Financial Results for the Fiscal Year Ended December 31, 2014

Formycon AG reported preliminary consolidated financial results for the fiscal year ended December 31, 2014. For the year, the company reported sales revenue and other income totaling EUR 12.67 million compared to EUR 0.41 million a year ago. EBITDA for the year was EUR 1.94 million compared to LBITDA of EUR 6.64 million a year ago, while net income came in at EUR 0.86 million compared to loss of EUR 7.74 million a year ago.

Formycon AG Reports Earnings Results for the First Half of 2014; Provides EBITDA Outlook for the full year 2014

Formycon AG reported earnings results for the first half of 2014. In the first half of 2014, the company recorded a turnover of €7.4 million against €0.2 million reported last year. This increase is substantially due to the high revenues achieved as a result of the above mentioned licence agreement and the resulting development alliance. The company's EBITDA amounted to €2.6 million in the first half of 2014 against negative €3.5 million reported last year. Overall, the company expects to achieve positive EBITDA for the business year 2014.

Formycon AG Presents at German Equity Forum 2014, Nov-26-2014 09:30 AM

Formycon AG Presents at German Equity Forum 2014, Nov-26-2014 09:30 AM. Venue: Frankfurt, Germany. Speakers: Carsten Brockmeyer, Chief Executive Officer and Member of Executive Board, Nicolas Combé, Co-Founder, Chief Financial Officer and Member of Executive Board.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FYB:GR €27.69 EUR +0.075

FYB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FYB.
View Industry Companies

Industry Analysis


Industry Average

Valuation FYB Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FORMYCON AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at